Drugs / XL888
XL888
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03095781 | Jul 2017 → Jun 2021 | colorectal adenocarcinoma, pancreatic adenocarcinoma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02721459 | Sep 2016 → Oct 2019 overdue | melanoma, skin cancer | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01657591 | Jul 2012 → Sep 2016 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00796484 | Nov 2008 → Nov 2010 | cancer | Exelixis | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL888 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02721459 ↗ |
| Known as | Exel-4888 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297451 ↗ |
| Known as | Heat Shock Protein 90 Inhibitor XL888 | “Heat Shock Protein 90 Inhibitor XL888” NCT03095781 ↗ |
| Known as | Hsp90 Inhibitor XL888 | “Hsp90 Inhibitor XL888” NCT03095781 ↗ |
| Action | Inhibit | “XL888 is a potent and selective inhibitor of HSP90” NCT00796484 ↗ |
| Modality | Small molecule | — CHEMBL4297451 ↗ |
| Route | Oral | “Administered orally” NCT00796484 ↗ |